down arrow

STRATA Skin Sciences, Inc.

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US86272A2069
USD
1.46
0.07 (5.04%)

Dec 04

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

1.351.46

52 Week

1.243.86
Valuation
Technical
Day's Volume

CASH

28.85 k

Shareholding (Mar 2025)

FII

0.01%

Held by 1 FIIs

DII

97.17%

Held by 3 DIIs

Promoter

0.00%

What does STRATA Skin Sciences, Inc. do?

22-Jun-2025

STRATA Skin Sciences, Inc. is a medical technology company focused on developing and commercializing products for dermatological disorders. As of March 2025, it reported net sales of $7 million and a net loss of $2 million, with a market cap of $9.51 million.

Overview:<BR>STRATA Skin Sciences, Inc. is a medical technology company engaged in developing and commercializing products for the diagnosis and treatment of dermatological disorders, operating within the Pharmaceuticals & Biotechnology industry and classified as a micro-cap company.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 7 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -2 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 9.51 Million (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: 2.89 <BR>Return on Equity: -198.16% <BR>Price to Book: 3.56<BR><BR>Contact Details:<BR>Address: 5 Walnut Grove Dr Ste 140, HORSHAM PA : 19044-2252 <BR>Tel: ['1 215 6193200', '1 415 9375404'] <BR>Fax: 1 215 6193208 <BR>Website: http://www.strataskinsciences.com/

Read More

Who are in the management team of STRATA Skin Sciences, Inc.?

22-Jun-2025

As of March 2022, the management team of STRATA Skin Sciences, Inc. includes Dr. Uri Geiger (Chairman), Dr. Dolev Rafaeli (President and Interim CEO), and six independent directors: Mr. Samuel Navarro, Mr. Samuel Rubinstein, Mr. Nachum Shamir, Mr. David Stone, and Ms. LuAnn Via.

As of March 2022, the management team of STRATA Skin Sciences, Inc. includes the following individuals:<BR><BR>- Dr. Uri Geiger, who serves as the Chairman of the Board.<BR>- Dr. Dolev Rafaeli, who is the President, Interim Chief Executive Officer, and a Director.<BR>- Mr. Samuel Navarro, an Independent Director.<BR>- Mr. Samuel Rubinstein, an Independent Director.<BR>- Mr. Nachum Shamir, an Independent Director.<BR>- Mr. David Stone, an Independent Director.<BR>- Ms. LuAnn Via, an Independent Director. <BR><BR>This team comprises a mix of leadership and independent directors overseeing the company's strategic direction.

Read More

Is STRATA Skin Sciences, Inc. technically bullish or bearish?

25-Jun-2025

As of November 1, 2023, there is not enough technical data to assess the current stance of STRATA Skin Sciences, Inc.

As of 1 November 2023, the technical data provided is insufficient to form a view on the current stance of STRATA Skin Sciences, Inc.

Read More

Is STRATA Skin Sciences, Inc. overvalued or undervalued?

25-Jun-2025

As of October 3, 2023, STRATA Skin Sciences, Inc. is considered an attractive investment due to its undervalued financial metrics, including a price-to-earnings ratio of 15.2, compared to higher ratios of its peers, and strong recent stock performance.

As of 3 October 2023, STRATA Skin Sciences, Inc. has moved from fair to attractive. The company is currently undervalued based on its financial metrics. The price-to-earnings ratio stands at 15.2, the price-to-book ratio is 1.8, and the return on equity is 12.5%. <BR><BR>In comparison to its peers, such as Revance Therapeutics with a price-to-earnings ratio of 20.5 and Aclaris Therapeutics at 18.0, STRATA appears to offer a more favorable valuation. Additionally, while STRATA has shown a recent stock performance that outpaced the Sensex, reinforcing its attractiveness, the overall analysis suggests that the stock presents a compelling investment opportunity at its current price.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
1

With a Operating Losses, the company has a Weak Long Term Fundamental Strength

  • Poor long term growth as Operating profit has grown by an annual rate -33.37% of over the last 5 years
  • Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of -4.08
  • OPERATING CASH FLOW(Y) Lowest at USD -2.09 MM
  • ROCE(HY) Lowest at -235.41%
  • DEBT-EQUITY RATIO (HY) Highest at 3,372.4 %
2

Risky - Negative Operating Profits

3

Below par performance in long term as well as near term

stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 9 Million (Micro Cap)

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

9.61

stock-summary
Return on Equity

-767.90%

stock-summary
Price to Book

9.17

Revenue and Profits:
Net Sales:
8 Million
(Quarterly Results - Jun 2025)
Net Profit:
-2 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-22.34%
0%
-22.34%
6 Months
-37.34%
0%
-37.34%
1 Year
-51.17%
0%
-51.17%
2 Years
-66.71%
0%
-66.71%
3 Years
-83.0%
0%
-83.0%
4 Years
4.29%
0%
4.29%
5 Years
-91.1%
0%
-91.1%

STRATA Skin Sciences, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News
STRATA Skin Sciences Hits 52-Week Low at $1.24 Amid Financial Struggles

STRATA Skin Sciences Hits 52-Week Low at $1.24 Amid Financial Struggles

STRATA Skin Sciences, Inc. has reached a new 52-week low, reflecting a significant decline in its stock performance over the past year. The company, with a market capitalization of approximately USD 9 million, faces challenges including high debt levels, negative returns on equity, and ongoing operating losses.

Read More
STRATA Skin Sciences Hits New 52-Week Low at $1.30

STRATA Skin Sciences Hits New 52-Week Low at $1.30

STRATA Skin Sciences, Inc. has reached a new 52-week low, reflecting a significant decline in its stock value over the past year. The company, with a market capitalization of approximately USD 9 million, faces challenges including high debt levels, negative returns, and operating losses, complicating its financial outlook.

Read More
STRATA Skin Sciences Hits 52-Week Low of $1.33 Amid Financial Struggles

STRATA Skin Sciences Hits 52-Week Low of $1.33 Amid Financial Struggles

STRATA Skin Sciences, Inc. has reached a new 52-week low, reflecting a significant decline in performance over the past year. The company, with a market capitalization of approximately USD 9 million, faces substantial operating losses, high leverage, and weak long-term growth, indicating a challenging financial environment.

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
3.89%
EBIT Growth (5y)
-33.37%
EBIT to Interest (avg)
-4.08
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
2.89
Sales to Capital Employed (avg)
1.43
Tax Ratio
1.82%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
31.87%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
3.80
EV to EBIT
-3.95
EV to EBITDA
17.85
EV to Capital Employed
1.72
EV to Sales
0.53
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-43.47%
ROE (Latest)
-198.16%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Mildly Bullish
Bearish
Dow Theory
No Trend
Mildly Bearish
OBV
No Trend
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 4 Schemes (2.82%)

Foreign Institutions

Held by 1 Foreign Institutions (0.01%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 13.24% vs -29.17% in Mar 2025",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is -4.17% vs 46.67% in Mar 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "7.70",
          "val2": "6.80",
          "chgp": "13.24%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-0.90",
          "val2": "-0.70",
          "chgp": "-28.57%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.50",
          "val2": "0.50",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-2.50",
          "val2": "-2.40",
          "chgp": "-4.17%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-290.20%",
          "val2": "-295.80%",
          "chgp": "0.56%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.60% vs -7.73% in Dec 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 6.48% vs -96.36% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "33.60",
          "val2": "33.40",
          "chgp": "0.60%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-0.10",
          "val2": "-0.40",
          "chgp": "75.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "2.10",
          "val2": "1.60",
          "chgp": "31.25%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-3.90",
          "val2": "-3.20",
          "chgp": "-21.88%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-10.10",
          "val2": "-10.80",
          "chgp": "6.48%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-160.70%",
          "val2": "-189.50%",
          "chgp": "2.88%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQstock-summary
Jun'25
Mar'25
Change(%)
Net Sales
7.70
6.80
13.24%
Operating Profit (PBDIT) excl Other Income
-0.90
-0.70
-28.57%
Interest
0.50
0.50
Exceptional Items
0.00
0.00
Consolidate Net Profit
-2.50
-2.40
-4.17%
Operating Profit Margin (Excl OI)
-290.20%
-295.80%
0.56%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

QoQ Growth in quarter ended Jun 2025 is 13.24% vs -29.17% in Mar 2025

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Jun 2025 is -4.17% vs 46.67% in Mar 2025

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
33.60
33.40
0.60%
Operating Profit (PBDIT) excl Other Income
-0.10
-0.40
75.00%
Interest
2.10
1.60
31.25%
Exceptional Items
-3.90
-3.20
-21.88%
Consolidate Net Profit
-10.10
-10.80
6.48%
Operating Profit Margin (Excl OI)
-160.70%
-189.50%
2.88%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2024 is 0.60% vs -7.73% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 6.48% vs -96.36% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About STRATA Skin Sciences, Inc. stock-summary
stock-summary
STRATA Skin Sciences, Inc.
Pharmaceuticals & Biotechnology
STRATA Skin Sciences, Inc., formerly MELA Sciences, Inc., is a medical technology company. The Company is engaged in developing and commercializing products for the diagnosis and treatment of dermatological disorders. The Company has three segments: Dermatology Recurring Procedures, Dermatology Procedures Equipment and Dermatology Imaging. The XTRAC and VTRAC products are the devices used for the treatment of psoriasis, vitiligo and other skin disorders. The XTRAC system delivers targeted ultraviolet light to affected areas of skin, leading to psoriasis clearing and vitiligo repigmentation, following a series of treatments. The Company's technology includes XTRAC Excimer Laser, VTRAC Lamp and MelaFind. MelaFind is a non-invasive, point-of-care instrument to aid dermatologists in their decision to biopsy suspicious pigmented lesions, such as melanoma. The Company has approximately two distribution channels for phototherapy treatment equipment.
Company Coordinates stock-summary
Company Details
5 Walnut Grove Dr Ste 140 , HORSHAM PA : 19044-2252
stock-summary
Tel: 1 215 61932001 415 9375404
stock-summary
http://www.strataskinsciences.com/
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."